Diagnostics as a Service Hurdle provides end-to-end, API-first diagnostic infrastructure enabling rapid go-live for digital health companies, clinics, and pharma brands. This suggests opportunities to upsell to firms needing scalable lab analysis, sample collection, logistics, and AI-driven biomarker discovery on a unified platform.

Partnership Ecosystem Recent launches of the Partner Portal and Partner Phlebotomy Booking Module indicate a growing focus on B2B collaborations. Target potential partners such as clinics, telemedicine providers, and lab networks that could benefit from streamlined scheduling, integration, and co-branded services.

Saliva and Biomarkers Introduction of saliva-based DNA methylation biomarkers for systemic chronic inflammation signals an expansion into novel, non-invasive tests. Engage pharma and research organizations pursuing aging, inflammation, and precision health programs with scalable biomarker offerings.

Home Testing Footprint Past launches of home-testing products (vitamin D, HbA1c) demonstrate consumer-oriented capabilities and direct-to-consumer potential. There is opportunity to propose partnerships for at-home diagnostic kits integrated with lab analysis and compliant data workflows.

Compliance and Scale With an API-first, cloud-based stack on AWS and existing lab capabilities, Hurdle is positioned for enterprises seeking compliant, scalable diagnostics. Sales plays can focus on enterprise health systems, large digital health platforms, and pharma brands requiring reliable data governance and rapid deployment.